Jaguar Health（JAGX）株式概要
商業段階の製薬会社であるジャガー・ヘルス社は、胃腸障害に苦しむ人々や動物のために、植物由来の処方箋薬の開発に注力している。 詳細
JAGX Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Jaguar Health, Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$2.31 |
| 52週高値 | US$96.25 |
| 52週安値 | US$2.12 |
| ベータ | -0.094 |
| 1ヶ月の変化 | -14.13% |
| 3ヶ月変化 | -83.08% |
| 1年変化 | -97.56% |
| 3年間の変化 | -99.90% |
| 5年間の変化 | -99.90% |
| IPOからの変化 | -99.90% |
最新ニュース
ナラティブの更新 • Jun 25
JAGX: Corporate Transactions And Nasdaq Compliance Will Drive Future Upside Repricing
The analyst price target for Jaguar Health is unchanged at $262.50, with analysts pointing to a steady fair value estimate, the same $262.50 valuation input, and slightly adjusted assumptions for revenue growth and profit margin to support their view. What’s in the News for Jaguar Health Jaguar Health is reviewing multiple potential corporate transactions, including mergers, reverse mergers, acquisitions, partnerships, joint ventures and licensing deals, as it works toward clinical completion for a crofelemer-based drug candidate targeting rare intestinal failure diseases.ナラティブの更新 • Jun 06
JAGX: Nasdaq Listing Risk Will Set Up Future Upside Repricing
Narrative Update on Jaguar Health The analyst price target for Jaguar Health has been reduced by $262.50. Analysts point to sharply lower revenue growth expectations and a modestly higher projected profit margin as key reasons for the reset.ナラティブの更新 • May 17
JAGX: Nasdaq Delisting Risk Will Set Up Future Upside Repricing
Analysts have reset Jaguar Health's fair value estimate from $7.50 to $262.50, reflecting a revised view on the discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News Nasdaq staff issued a delisting notice on May 1, 2026, citing Jaguar Health's publicly held shares of common stock of approximately 401,226 after the 1 for 35 reverse stock split, which is below the 500,000 minimum required for continued listing under Nasdaq Listing Rule 5550(a)(4) (Nasdaq notice).Recent updates
ナラティブの更新 • Jun 25
JAGX: Corporate Transactions And Nasdaq Compliance Will Drive Future Upside Repricing
The analyst price target for Jaguar Health is unchanged at $262.50, with analysts pointing to a steady fair value estimate, the same $262.50 valuation input, and slightly adjusted assumptions for revenue growth and profit margin to support their view. What’s in the News for Jaguar Health Jaguar Health is reviewing multiple potential corporate transactions, including mergers, reverse mergers, acquisitions, partnerships, joint ventures and licensing deals, as it works toward clinical completion for a crofelemer-based drug candidate targeting rare intestinal failure diseases.ナラティブの更新 • Jun 06
JAGX: Nasdaq Listing Risk Will Set Up Future Upside Repricing
Narrative Update on Jaguar Health The analyst price target for Jaguar Health has been reduced by $262.50. Analysts point to sharply lower revenue growth expectations and a modestly higher projected profit margin as key reasons for the reset.ナラティブの更新 • May 17
JAGX: Nasdaq Delisting Risk Will Set Up Future Upside Repricing
Analysts have reset Jaguar Health's fair value estimate from $7.50 to $262.50, reflecting a revised view on the discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News Nasdaq staff issued a delisting notice on May 1, 2026, citing Jaguar Health's publicly held shares of common stock of approximately 401,226 after the 1 for 35 reverse stock split, which is below the 500,000 minimum required for continued listing under Nasdaq Listing Rule 5550(a)(4) (Nasdaq notice).ナラティブの更新 • Apr 25
JAGX: Nasdaq Listing Risk Will Set Up Future Upside Repricing
Analysts have adjusted their price target for Jaguar Health to $7.50, reflecting updated views on the company’s profit margin profile and long term P/E expectations, while keeping fair value and growth assumptions broadly in line with prior estimates. What's in the News Jaguar Health filed its 10-K on April 7, 2026, with auditor RBSM LLP issuing an unqualified opinion.ナラティブの更新 • Apr 10
JAGX: Nasdaq Listing Risk Will Drive Future Upside Repricing Potential
Analysts have adjusted their price target for Jaguar Health to reflect updated assumptions for slower revenue growth, largely unchanged profit margins, and a substantially higher forward P/E multiple. What's in the News Jaguar Health reported that it will be unable to file its next 10-K by the SEC deadline, indicating a delay in required financial reporting (SEC filing announcement).ナラティブの更新 • Mar 27
JAGX: Nasdaq Listing Risk Will Trigger Future Upside Repricing Potential
Analysts now place Jaguar Health's price target at $7.50, consistent with the prior $7.50 view. They cite broadly unchanged fair value, discount rate and revenue growth assumptions, alongside a slightly lower profit margin outlook and a modestly higher future P/E expectation.ナラティブの更新 • Mar 12
JAGX: Nasdaq Listing Risk Will Set Up Potential Upside Repricing
Analysts maintained their $7.50 price target for Jaguar Health, citing a higher discount rate and slightly lower assumed profit margins, partly offset by a higher future P/E assumption, as the key factors in their updated model. What's in the News On March 5, 2026, Nasdaq notified Jaguar Health that its common stock had closed below the minimum US$1.00 bid price for 30 consecutive business days, leaving the company out of compliance with Nasdaq Listing Rule 5550(a)(2) (Key Developments).ナラティブの更新 • Feb 25
JAGX: Short Term Funding Will Support Improved Profitability Expectations
Analysts have reset their price target for Jaguar Health from $28 to $7.50. They now apply a lower discount rate, more moderate revenue growth expectations, slightly tighter profit margin assumptions, and a higher future P/E multiple in their updated model.
ナラティブの更新 • Feb 09
JAGX: Recent Debt Financing Will Support Upside Potential
Analysts have slightly adjusted their fair value estimate for Jaguar Health to US$35.00. This reflects small tweaks to discount rate, revenue growth and future P/E assumptions rather than a major shift in their overall thesis.ナラティブの更新 • Jan 25
JAGX: Near Term Debt Funding And Shareholder Votes Will Support Upside Potential
Analysts have adjusted their price target for Jaguar Health to US$35.00, reflecting updated views on fair value, discount rate, growth assumptions and future P/E that they consider better aligned with the stock's current risk and return profile. What's in the News Jaguar Health entered into a securities purchase agreement on January 6, 2026, for unsecured promissory notes with an aggregate principal amount of US$350,000, carrying 6% annual interest and maturing one month after issuance (Key Developments).ナラティブの更新 • Jan 11
JAGX: Upcoming Debt Funding And Shareholder Votes Will Support Upside Potential
Analysts have slightly adjusted their fair value target for Jaguar Health to US$35.00, reflecting updated assumptions around the discount rate, revenue growth, profit margin, and future P/E, while keeping the headline price target level unchanged. What's in the News On November 24, 2025, Jaguar Health, Inc.ナラティブの更新 • Dec 26
JAGX: Future Private Placements Will Support Balance Sheet And Upside Potential
Analysts have raised their price target on Jaguar Health to 35.00 dollars, reflecting slightly higher long term revenue growth assumptions and a modestly higher discount rate. Together these factors keep fair value effectively unchanged while acknowledging incremental upside potential.ナラティブの更新 • Dec 12
JAGX: Future Capital Raises Will Strengthen Balance Sheet And Support Upside Potential
Analysts have modestly reduced their price target on Jaguar Health to reflect a lower fair value estimate of 35 dollars from 40 dollars, even as they factor in stronger revenue growth and a higher future price to earnings multiple, partially offset by slightly softer profit margin assumptions and a lower discount rate. What's in the News Jaguar Health closed a private placement transaction on November 24, 2025, further advancing its ongoing capital raising efforts (Key Developments).分析記事 • Aug 29
Slammed 27% Jaguar Health, Inc. (NASDAQ:JAGX) Screens Well Here But There Might Be A Catch
To the annoyance of some shareholders, Jaguar Health, Inc. ( NASDAQ:JAGX ) shares are down a considerable 27% in the...分析記事 • Jul 02
Investors Give Jaguar Health, Inc. (NASDAQ:JAGX) Shares A 43% Hiding
The Jaguar Health, Inc. ( NASDAQ:JAGX ) share price has fared very poorly over the last month, falling by a substantial...
新しいナラティブ • Apr 18
FDA And EMA Fast-Track Approvals Will Advance Orphan Treatments
New collaborations and regulatory approvals could quicken market entry, increase revenue, and improve earnings through enhanced access to global markets for orphan disease treatments.分析記事 • Feb 05
Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 30%
Jaguar Health, Inc. ( NASDAQ:JAGX ) shares have had a horrible month, losing 30% after a relatively good period...分析記事 • Nov 09
Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 27%
Jaguar Health, Inc. ( NASDAQ:JAGX ) shareholders won't be pleased to see that the share price has had a very rough...分析記事 • Nov 09
Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 27%
Jaguar Health, Inc. ( NASDAQ:JAGX ) shares have had a horrible month, losing 27% after a relatively good period...分析記事 • Jul 24
Jaguar Health, Inc. (NASDAQ:JAGX) Stock's 55% Dive Might Signal An Opportunity But It Requires Some Scrutiny
To the annoyance of some shareholders, Jaguar Health, Inc. ( NASDAQ:JAGX ) shares are down a considerable 55% in the...分析記事 • May 24
Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 49%
Jaguar Health, Inc. ( NASDAQ:JAGX ) shares have retraced a considerable 49% in the last month, reversing a fair amount...分析記事 • Mar 29
Jaguar Health, Inc. (NASDAQ:JAGX) Shares Fly 55% But Investors Aren't Buying For Growth
Jaguar Health, Inc. ( NASDAQ:JAGX ) shareholders are no doubt pleased to see that the share price has bounced 55% in...分析記事 • Jan 22
Jaguar Health, Inc. (NASDAQ:JAGX) Not Doing Enough For Some Investors As Its Shares Slump 39%
Unfortunately for some shareholders, the Jaguar Health, Inc. ( NASDAQ:JAGX ) share price has dived 39% in the last...分析記事 • Jun 10
Positive Sentiment Still Eludes Jaguar Health, Inc. (NASDAQ:JAGX) Following 32% Share Price Slump
To the annoyance of some shareholders, Jaguar Health, Inc. ( NASDAQ:JAGX ) shares are down a considerable 32% in the...分析記事 • Jan 23
Jaguar Health (NASDAQ:JAGX) Is Carrying A Fair Bit Of Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...株主還元
| JAGX | US Pharmaceuticals | US 市場 | |
|---|---|---|---|
| 7D | -17.8% | -2.0% | 0.7% |
| 1Y | -97.6% | 44.4% | 20.6% |
業界別リターン: JAGX過去 1 年間で44.4 % の収益を上げたUS Pharmaceuticals業界を下回りました。
リターン対市場: JAGXは、過去 1 年間で20.6 % のリターンを上げたUS市場を下回りました。
価格変動
| JAGX volatility | |
|---|---|
| JAGX Average Weekly Movement | 21.9% |
| Pharmaceuticals Industry Average Movement | 9.3% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.2% |
安定した株価: JAGXの株価は、 US市場と比較して過去 3 か月間で変動しています。
時間の経過による変動: JAGXの weekly volatility ( 22% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| n/a | 47 | Lisa Conte | jaguar.health |
商業段階の製薬会社であるジャガー・ヘルス社は、胃腸障害に悩む人々や動物のための植物由来の処方薬の開発に注力している。アニマルヘルスとヒューマンヘルスの2つのセグメントで事業を展開している。同社は、コンパニオンアニマルおよび生産動物用の処方薬および非処方薬、ならびにヒト用製品の開発・商業化に注力している。主な医療用医薬品は、抗レトロウイルス療法を受けている成人のHIV/AIDS患者における非感染性下痢の症状緩和を目的とした抗分泌性止瀉薬のマイテシと、犬の化学療法誘発性下痢に対する医療用医薬品のカナレビア-CA1である。また、抗分泌性止瀉薬であるクロフェレマーを開発中であり、成人がん患者の下痢予防を対象とした第III相臨床試験、腸管機能不全を伴う短腸症候群や微小絨毛封入体症、下痢優位型過敏性腸症候群、特発性／機能性下痢を含む希少／希少疾患を対象とした第II相臨床試験を実施中である。さらに、がん治療に関連した下痢を対象とした第III相臨床試験および過敏性腸症候群を対象とした第II相臨床試験中のマイテシ、中等度から重度の下痢の症状緩和および治療を対象とした第I相臨床試験中の第2世代止瀉薬NP-300を開発中である。本社はカリフォルニア州サンフランシスコ。
Jaguar Health, Inc. 基礎のまとめ
| JAGX 基礎統計学 | |
|---|---|
| 時価総額 | US$1.39m |
| 収益（TTM） | -US$50.13m |
| 売上高(TTM) | US$29.57m |
0.0x
P/Sレシオ0.0x
PER（株価収益率JAGX は割高か？
公正価値と評価分析を参照収益と収入
| JAGX 損益計算書（TTM） | |
|---|---|
| 収益 | US$29.57m |
| 売上原価 | US$4.42m |
| 売上総利益 | US$25.15m |
| その他の費用 | US$75.28m |
| 収益 | -US$50.13m |
直近の収益報告
Mar 31, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | -83.11 |
| グロス・マージン | 85.06% |
| 純利益率 | -169.52% |
| 有利子負債／自己資本比率 | -527.7% |
JAGX の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/07/12 01:17 |
| 終値 | 2026/07/10 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Jaguar Health, Inc. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2
| アナリスト | 機関 |
|---|---|
| Robert LeBoyer | Aegis Capital Corporation |
| Christian Orquera | First Berlin Equity Research GmbH |